Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 5/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 7/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.33 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.30 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20234525 | 1.00 | SLC6A1 (0.33) | SLC6A1SLC6A11KCNH2TP53CYP3A4 | |
| SCHEMBL19958985 | 0.93 | SLC6A1 (0.36) | SLC6A1SLC6A11KCNH2TP53CYP3A4 | |
| SCHEMBL19958983 | 0.93 | SLC6A1 (0.36) | SLC6A1SLC6A11KCNH2TP53CYP3A4 | |
| SCHEMBL19958980 | 0.93 | SLC6A1 (0.36) | SLC6A1SLC6A11KCNH2TP53CYP3A4 | |
| SCHEMBL20325210 | 0.88 | SLC6A2 (0.31) | ALDH1A1SMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23314115 | 0.82 | SLC6A2 (0.34) | SLC6A1SLC6A11KCNH2TP53CYP3A4 | |
| SCHEMBL19958982 | 0.81 | SLC6A1 (0.36) | SLC6A1SLC6A11KCNH2TP53CYP3A4 | |
| SCHEMBL21471908 | 0.80 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22006112 | 0.80 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10192211 | 0.79 | SMN1; SMN2 (0.34) | KCNH2TP53CYP3A4CACNA1ISMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| US-20220267305-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-08-25 | — | — | US | disclosed |
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | UNIV YALE (US) | 2020-04-23 | — | — | US | disclosed |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | BTK, CBL, CRBN | SLC6A1 4654/4885SLC6A11 4612/4885KCNH2 4741/4885 |
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | SLC6A1 4238/4885SLC6A11 4351/4885KCNH2 4792/4885 |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | EGFR, ERBB2, ERBB3 | SLC6A1 4242/4885SLC6A11 4441/4885KCNH2 4873/4885 |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | SLC6A1 521/4885SLC6A11 532/4885KCNH2 3892/4885 |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | EGFR, ERBB2, ERBB3 | SLC6A1 4242/4885SLC6A11 4441/4885KCNH2 4873/4885 |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | SLC6A1 4019/4885SLC6A11 4216/4885KCNH2 4822/4885 |
| US-20220267305-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | SLC6A1 3733/4885SLC6A11 3700/4885KCNH2 4852/4885 |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | MDM2, CRBN, FLT3 | SLC6A1 3790/4885SLC6A11 3823/4885KCNH2 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.